WO1993022433A3 - Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament - Google Patents
Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament Download PDFInfo
- Publication number
- WO1993022433A3 WO1993022433A3 PCT/DE1993/000374 DE9300374W WO9322433A3 WO 1993022433 A3 WO1993022433 A3 WO 1993022433A3 DE 9300374 W DE9300374 W DE 9300374W WO 9322433 A3 WO9322433 A3 WO 9322433A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament
- viruses
- animals
- human beings
- retro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93911729A EP0677103A1 (fr) | 1992-04-28 | 1993-04-28 | Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATPCT/EP92/00923 | 1992-04-28 | ||
EP9200923 | 1992-04-28 | ||
DE4238879 | 1992-11-19 | ||
DEP4238879.1 | 1992-11-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993022433A2 WO1993022433A2 (fr) | 1993-11-11 |
WO1993022433A3 true WO1993022433A3 (fr) | 1994-07-07 |
Family
ID=25920549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1993/000374 WO1993022433A2 (fr) | 1992-04-28 | 1993-04-28 | Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4259193A (fr) |
WO (1) | WO1993022433A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0650370A4 (fr) * | 1992-06-08 | 1995-11-22 | Univ California | Procedes et compositions permettant de cibler des tissus specifiques. |
DE19503082A1 (de) * | 1995-02-01 | 1996-08-08 | Univ Ludwigs Albert | Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240332A2 (fr) * | 1986-04-02 | 1987-10-07 | Pioneer Hi-Bred International, Inc. | Plantes résistantes aux virus comportant l'ARN anti-sens |
EP0278667A2 (fr) * | 1987-02-09 | 1988-08-17 | Mycogen Plant Science, Inc. | Virus d'ARN hybride |
WO1990005538A1 (fr) * | 1988-11-14 | 1990-05-31 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Capsides de parvovirus |
EP0387775A1 (fr) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Unité génétique pour inhiber la fonction d'ARN |
WO1990012087A1 (fr) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Particule virale infectieuse ciblee a replication defectueuse |
WO1992005266A2 (fr) * | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Cellules d'encapsidation |
WO1992006180A1 (fr) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Ciblage de virus et de cellules pour leur inclusion selective dans des cellules |
-
1993
- 1993-04-28 WO PCT/DE1993/000374 patent/WO1993022433A2/fr not_active Application Discontinuation
- 1993-04-28 AU AU42591/93A patent/AU4259193A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240332A2 (fr) * | 1986-04-02 | 1987-10-07 | Pioneer Hi-Bred International, Inc. | Plantes résistantes aux virus comportant l'ARN anti-sens |
EP0278667A2 (fr) * | 1987-02-09 | 1988-08-17 | Mycogen Plant Science, Inc. | Virus d'ARN hybride |
WO1990005538A1 (fr) * | 1988-11-14 | 1990-05-31 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Capsides de parvovirus |
EP0387775A1 (fr) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Unité génétique pour inhiber la fonction d'ARN |
WO1990012087A1 (fr) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Particule virale infectieuse ciblee a replication defectueuse |
WO1992005266A2 (fr) * | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Cellules d'encapsidation |
WO1992006180A1 (fr) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Ciblage de virus et de cellules pour leur inclusion selective dans des cellules |
Non-Patent Citations (1)
Title |
---|
GAREIS, M. ET AL.: "Homologous recombination of exogenous DNA fragments with genomic DNA in somatic cells of mice", CELLULAR AND MOLECULAR BIOLOGY, vol. 37, no. 2, 1991, pages 191 - 203, XP000406056 * |
Also Published As
Publication number | Publication date |
---|---|
WO1993022433A2 (fr) | 1993-11-11 |
AU4259193A (en) | 1993-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU8335291A (en) | Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals | |
CA2214503A1 (fr) | Methode de traitement de tumeurs | |
IL105366A0 (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
PT668763E (pt) | Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento | |
ZA95679B (en) | Products containing G-CSF and TNF binding protein | |
DE3650505T2 (de) | AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung. | |
WO1993022433A3 (fr) | Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament | |
DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
GB8917323D0 (en) | Methods and pharmaceutical compositions for the treatment of ophthalmic diseases | |
US5547672A (en) | Accelerated wound healing | |
GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
AU5643299A (en) | Humic acid and its use in the treatment of various conditions | |
HK1042239A1 (en) | Bupropion to treat viral diseases. | |
EP0668771A4 (fr) | Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes. | |
RU94006478A (ru) | Способ световой терапии | |
Aliev et al. | The possibility of the use of interferon in the treatment of alcoholism. | |
RU92011168A (ru) | Препарат для лечения гинекологических заболеваний | |
RU2002131990A (ru) | Способ лечения пострадавших с черепно-мозговой травмой в ранний посттравматический период | |
ZA938915B (en) | Treatment of viral infections by conjunctive therapy with acyclovir-like compounds and a 2'-vynyl substituted nucleoside analog | |
FARSHATOV | The role of radioprotectors in the effectiveness of the treatment of combined radiation injuries(Vliianie radioproektorov na effektivnost' lecheniia kombinirovannykh radiatsionnykh porazhenii(Obzor literatury)) | |
RU94043033A (ru) | Способ коррекции и модуляции иммуногомеостаза при заболеваниях внутренних органов и нервной системы | |
MD197G2 (ro) | Preparat şi procedeu de tratare a hipogalactiei | |
Juca et al. | Antimicrobial therapy with cefoxitin sodium in vascular surgery and angiology: Clinical and laboratorial survey. | |
RU94002713A (ru) | Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда) | |
RU92011195A (ru) | Способ уменьшения дозы химиопрепаратов, используемых для лечения инфекционных заболеваний при одновременном повышении их терапевтической эффективности |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993911729 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993911729 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1993911729 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993911729 Country of ref document: EP |